NASDAQ:SCYX - Scynexis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.63 +0.20 (+13.99 %)
(As of 05/21/2018 02:36 AM ET)
Previous Close$1.63
Today's Range$1.40 - $1.66
52-Week Range$1.05 - $2.50
Volume2.28 million shs
Average Volume378,384 shs
Market Capitalization$76.35 million
P/E Ratio-1.61
Dividend YieldN/A
Beta0.27

About Scynexis (NASDAQ:SCYX)

Scynexis logoSCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485

Debt

Debt-to-Equity Ratio0.30
Current Ratio5.93
Quick Ratio5.93

Price-To-Earnings

Trailing P/E Ratio-1.61
Forward P/E Ratio-2.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales293.65
Cash FlowN/A
Price / CashN/A
Book Value$0.79 per share
Price / Book2.06

Profitability

EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-9,450.00%
Return on Equity-78.78%
Return on Assets-43.38%

Miscellaneous

Employees19
Outstanding Shares46,840,000

Scynexis (NASDAQ:SCYX) Frequently Asked Questions

What is Scynexis' stock symbol?

Scynexis trades on the NASDAQ under the ticker symbol "SCYX."

How were Scynexis' earnings last quarter?

Scynexis (NASDAQ:SCYX) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.06. The business had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.10 million. Scynexis had a negative return on equity of 78.78% and a negative net margin of 9,450.00%. View Scynexis' Earnings History.

What price target have analysts set for SCYX?

5 equities research analysts have issued 1-year target prices for Scynexis' stock. Their predictions range from $4.00 to $6.00. On average, they expect Scynexis' share price to reach $5.25 in the next twelve months. View Analyst Ratings for Scynexis.

Who are some of Scynexis' key competitors?

Who are Scynexis' key executives?

Scynexis' management team includes the folowing people:
  • Dr. Marco Taglietti, Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Eric Francois, Chief Financial Officer (Age 43)
  • Mr. David Gonzalez Angulo M.D., Chief Medical Officer (Age 53)
  • Mr. Scott Sukenick J.D., Gen. Counsel
  • Dr. Rajeshwar Motheram Ph.D., VP of Pharmaceutical Devel.

Has Scynexis been receiving favorable news coverage?

Media headlines about SCYX stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Scynexis earned a media sentiment score of 0.09 on Accern's scale. They also assigned media stories about the company an impact score of 47.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Scynexis' major shareholders?

Scynexis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (14.66%), Caxton Corp (4.09%), DAFNA Capital Management LLC (3.49%), CVI Holdings LLC (2.78%), Rock Springs Capital Management LP (1.75%) and Iguana Healthcare Management LLC (0.85%). Company insiders that own Scynexis stock include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti, Patrick Machado and Scott Sukenick. View Institutional Ownership Trends for Scynexis.

Which major investors are buying Scynexis stock?

SCYX stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Caxton Corp, CVI Holdings LLC, DAFNA Capital Management LLC, Iguana Healthcare Management LLC and Rock Springs Capital Management LP. Company insiders that have bought Scynexis stock in the last two years include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti, Patrick Machado and Scott Sukenick. View Insider Buying and Selling for Scynexis.

How do I buy shares of Scynexis?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Scynexis' stock price today?

One share of SCYX stock can currently be purchased for approximately $1.63.

How big of a company is Scynexis?

Scynexis has a market capitalization of $76.35 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Scynexis employs 19 workers across the globe.

How can I contact Scynexis?

Scynexis' mailing address is 101 HUDSON STREET SUITE 3610, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]


MarketBeat Community Rating for Scynexis (SCYX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about Scynexis and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Scynexis (NASDAQ:SCYX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Scynexis in the last 12 months. Their average twelve-month price target is $5.25, suggesting that the stock has a possible upside of 222.09%. The high price target for SCYX is $6.00 and the low price target for SCYX is $4.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.832.832.83
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.25$8.25$10.00$9.50
Price Target Upside: 222.09% upside560.00% upside446.45% upside419.13% upside

Scynexis (NASDAQ:SCYX) Consensus Price Target History

Price Target History for Scynexis (NASDAQ:SCYX)

Scynexis (NASDAQ:SCYX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Roth CapitalInitiated CoverageBuy$6.00LowView Rating Details
5/7/2018HC WainwrightInitiated CoverageBuy$5.00HighView Rating Details
4/10/2018Seaport Global SecuritiesInitiated CoverageBuy$4.00HighView Rating Details
10/24/2017GuggenheimInitiated CoverageBuy$6.00N/AView Rating Details
5/30/2017AegisReiterated RatingBuyMediumView Rating Details
5/9/2017Needham & Company LLCDowngradeBuy ➝ HoldHighView Rating Details
3/3/2017Royal Bank of CanadaReiterated RatingOutperform$15.00 ➝ $11.00N/AView Rating Details
10/7/2016WBB SecuritiesUpgradeBuy ➝ Strong-Buy$8.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Scynexis (NASDAQ:SCYX) Earnings History and Estimates Chart

Earnings by Quarter for Scynexis (NASDAQ:SCYX)

Scynexis (NASDAQ:SCYX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.22)($0.22)($0.22)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.20)($0.20)($0.20)
Q4 20181($0.24)($0.24)($0.24)

Scynexis (NASDAQ SCYX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.1750)($0.12)$0.10 million$0.06 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.27)$0.06 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.30)($0.27)$0.06 million$0.06 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.16)$0.06 million$0.06 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.37)($0.21)$0.06 millionViewN/AView Earnings Details
11/7/2016Q3 2016($0.38)($0.35)$0.10 million$0.06 millionViewN/AView Earnings Details
8/8/2016Q216($0.52)($0.56)$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)$0.06 millionViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)$0.06 millionViewN/AView Earnings Details
8/19/2015Q2 2015($0.53)$0.06 millionViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)$5.30 millionViewN/AView Earnings Details
11/13/2014($0.53)($0.45)$4.38 millionViewN/AView Earnings Details
8/13/2014Q2 2014($2.12)$4.64 millionViewN/AView Earnings Details
6/16/2014Q1 2014($21.53)$4.71 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Scynexis (NASDAQ:SCYX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Scynexis (NASDAQ SCYX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 18.50%
Insider Trading History for Scynexis (NASDAQ:SCYX)
Institutional Ownership by Quarter for Scynexis (NASDAQ:SCYX)

Scynexis (NASDAQ SCYX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Gonzalez David AnguloInsiderBuy6,000$1.36$8,160.00101,790View SEC Filing  
3/8/2018David C HastingsDirectorBuy11,834$1.69$19,999.4631,834View SEC Filing  
3/8/2018Eric FrancoisCFOBuy5,917$1.69$9,999.7324,917View SEC Filing  
3/8/2018Gonzalez David AnguloInsiderBuy14,790$1.69$24,995.1088,790View SEC Filing  
3/8/2018Marco TagliettiCEOBuy100,000$1.69$169,000.00404,000View SEC Filing  
3/8/2018Scott SukenickGeneral CounselBuy2,959$1.69$5,000.712,959View SEC Filing  
9/22/2017Marco TagliettiCEOBuy10,000$2.23$22,300.00303,000View SEC Filing  
8/23/2017Marco TagliettiCEOBuy5,000$1.85$9,250.00287,007View SEC Filing  
8/15/2017Marco TagliettiCEOBuy10,000$1.61$16,100.00287,000View SEC Filing  
8/11/2017Gonzalez David AnguloInsiderBuy10,000$1.55$15,500.0072,000View SEC Filing  
6/21/2017David C HastingsDirectorBuy20,000$1.75$35,000.0020,000View SEC Filing  
5/12/2017Gonzalez David AnguloInsiderBuy15,000$1.70$25,500.0062,000View SEC Filing  
5/12/2017Marco TagliettiCEOBuy25,000$1.69$42,250.00277,000View SEC Filing  
12/21/2016Marco TagliettiCEOBuy25,000$3.30$82,500.00251,000View SEC Filing  
12/16/2016Gonzalez David AnguloInsiderBuy4,000$3.25$13,000.0046,000View SEC Filing  
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.0060,000View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.008,850View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.0015,000View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.0040,000View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00225,000View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.004,225View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04124,754View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00119,000View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00110,500View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00106,000View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07100,000View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.0077,267View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.3652,267View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.0050,000View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Scynexis (NASDAQ SCYX) News Headlines

Source:
DateHeadline
Seaport Global Securities Comments on Scynexis Q2 2018 Earnings (SCYX)Seaport Global Securities Comments on Scynexis' Q2 2018 Earnings (SCYX)
www.americanbankingnews.com - May 18 at 7:08 AM
Financial Analysis: Retrophin (RTRX) versus Scynexis (SCYX)Financial Analysis: Retrophin (RTRX) versus Scynexis (SCYX)
www.americanbankingnews.com - May 13 at 11:16 PM
Scynexis (SCYX) Issues Quarterly  Earnings ResultsScynexis (SCYX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 1:31 PM
SCYNEXIS beats by $0.08, misses on revenueSCYNEXIS beats by $0.08, misses on revenue
seekingalpha.com - May 9 at 8:15 AM
Scynexis: 1Q Earnings SnapshotScynexis: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:14 AM
SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company UpdateSCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - May 8 at 5:45 PM
Scynexis (SCYX) Earns Buy Rating from Analysts at Roth CapitalScynexis (SCYX) Earns Buy Rating from Analysts at Roth Capital
www.americanbankingnews.com - May 8 at 2:46 PM
Scynexis (SCYX) Upgraded by Zacks Investment Research to "Buy"Scynexis (SCYX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 8 at 11:02 AM
Roth Capital Assumes SCYNEXIS (SCYX) at BuyRoth Capital Assumes SCYNEXIS (SCYX) at Buy
www.streetinsider.com - May 8 at 8:12 AM
Benzingas Top Upgrades, Downgrades For May 7, 2018Benzinga's Top Upgrades, Downgrades For May 7, 2018
www.benzinga.com - May 7 at 5:43 PM
Scynexis (SCYX) "Buy" Rating Reaffirmed at HC WainwrightScynexis' (SCYX) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - May 7 at 2:58 PM
UPDATE: HC Wainwright Starts SCYNEXIS (SCYX) at BuyUPDATE: HC Wainwright Starts SCYNEXIS (SCYX) at Buy
www.streetinsider.com - May 7 at 8:15 AM
Scynexis (SCYX) Given Consensus Rating of "Buy" by AnalystsScynexis (SCYX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 5 at 3:33 AM
Scynexis (SCYX) Upgraded to Hold by ValuEngineScynexis (SCYX) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 2 at 6:02 PM
Scynexis (SCYX) Granted FDA Fast Track & Qualified Infectious Disease Product Designation for Oral SCY-078Scynexis (SCYX) Granted FDA Fast Track & Qualified Infectious Disease Product Designation for Oral SCY-078
www.streetinsider.com - May 2 at 8:17 AM
SCYNEXISs Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention ...SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention ...
www.prnewswire.com - May 1 at 5:21 PM
SCYNEXISs Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVCSCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
finance.yahoo.com - May 1 at 5:21 PM
Achaogen (AKAO) vs. Scynexis (SCYX) Financial AnalysisAchaogen (AKAO) vs. Scynexis (SCYX) Financial Analysis
www.americanbankingnews.com - April 26 at 7:46 AM
SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and PneumocystisSCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
finance.yahoo.com - April 23 at 8:12 AM
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical ...Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical ...
www.prnewswire.com - April 20 at 5:25 PM
Generic Drugs Stocks Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXISGeneric Drugs Stocks' Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXIS
www.prnewswire.com - April 13 at 8:15 AM
Research Analysts Offer Predictions for Scynexis Q1 2018 Earnings (SCYX)Research Analysts Offer Predictions for Scynexis' Q1 2018 Earnings (SCYX)
www.americanbankingnews.com - April 12 at 7:09 AM
SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease ...SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease ...
www.prnewswire.com - April 10 at 5:33 PM
Scynexis (SCYX) Given Average Rating of "Buy" by AnalystsScynexis (SCYX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 10 at 9:13 AM
Scynexis (SCYX) Receives New Coverage from Analysts at Seaport Global SecuritiesScynexis (SCYX) Receives New Coverage from Analysts at Seaport Global Securities
www.americanbankingnews.com - April 10 at 8:30 AM
SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
finance.yahoo.com - April 10 at 8:19 AM
Scynexis (SCYX) Earns Buy Rating from Analysts at GuggenheimScynexis (SCYX) Earns Buy Rating from Analysts at Guggenheim
www.americanbankingnews.com - April 5 at 10:14 PM
Form 4 SCYNEXIS INC For: Apr 02 Filed by: Macdonald GuyForm 4 SCYNEXIS INC For: Apr 02 Filed by: Macdonald Guy
www.streetinsider.com - April 5 at 10:04 AM
Form 4 SCYNEXIS INC For: Mar 29 Filed by: Angulo Gonzalez DavidForm 4 SCYNEXIS INC For: Mar 29 Filed by: Angulo Gonzalez David
www.streetinsider.com - April 2 at 8:32 AM
SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference - PR Newswire (press release)SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:21 AM
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 - PR Newswire (press release)SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:42 AM
SCYNEXIS to Present at the 17th Annual Needham Healthcare ConferenceSCYNEXIS to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 8:42 AM
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
finance.yahoo.com - March 20 at 5:21 PM
SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company UpdateSCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
finance.yahoo.com - March 13 at 7:22 PM
Gonzalez David Angulo Buys 14,790 Shares of SCYNEXIS Inc (SCYX) StockGonzalez David Angulo Buys 14,790 Shares of SCYNEXIS Inc (SCYX) Stock
www.americanbankingnews.com - March 12 at 10:17 AM
SCYNEXIS Inc (SCYX) Director Buys $19,999.46 in StockSCYNEXIS Inc (SCYX) Director Buys $19,999.46 in Stock
www.americanbankingnews.com - March 12 at 10:17 AM
SCYNEXIS Inc (SCYX) CEO Buys $169,000.00 in StockSCYNEXIS Inc (SCYX) CEO Buys $169,000.00 in Stock
www.americanbankingnews.com - March 12 at 10:16 AM
SCYNEXIS to Present at the 30th Annual ROTH Conference - PR Newswire (press release)SCYNEXIS to Present at the 30th Annual ROTH Conference - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:13 AM
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants - PR Newswire (press release)SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:13 AM
Scynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants - StreetInsider.comScynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - March 7 at 8:13 AM
SCYNEXIS to Present at the 30th Annual ROTH ConferenceSCYNEXIS to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 7 at 8:13 AM
BRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And WarrantsBRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants
www.reuters.com - March 6 at 5:43 PM
Scynexis (SCYX) Prices $30M Public Offering of Common Stock, WarrantsScynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants
www.streetinsider.com - March 6 at 5:43 PM
SCYNEXIS Announces Launch of Public Offering of Common Stock and WarrantsSCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
finance.yahoo.com - March 5 at 5:52 PM
SCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from AnalystsSCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 28 at 7:42 PM
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of ... - PR Newswire (press release)SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of ... - PR Newswire (press release)
www.prnewswire.com - February 2 at 9:02 AM
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
finance.yahoo.com - February 1 at 9:16 AM
SCYNEXIS to Participate in the Cantor Antibiotics Summit - PR Newswire (press release)SCYNEXIS to Participate in the Cantor Antibiotics Summit - PR Newswire (press release)
www.prnewswire.com - January 12 at 11:15 AM
SCYNEXIS to Participate in the Cantor Antibiotics SummitSCYNEXIS to Participate in the Cantor Antibiotics Summit
finance.yahoo.com - January 12 at 11:15 AM
Celgene (CELG) & SCYNEXIS (SCYX) Critical SurveyCelgene (CELG) & SCYNEXIS (SCYX) Critical Survey
www.americanbankingnews.com - January 9 at 7:08 PM

SEC Filings

Scynexis (NASDAQ:SCYX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Scynexis (NASDAQ:SCYX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Scynexis (NASDAQ SCYX) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.